Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
April 26, 2024 07:15 ET
|
Apellis Pharmaceuticals, Inc.
Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA’s expert groupsApellis anticipates a CHMP opinion no later than July 2024 ...
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
April 23, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the 23rd Annual Needham Virtual...
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
March 11, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 07:05 ET
|
Apellis Pharmaceuticals, Inc.
Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 26, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences: TD...
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 4 new employees with a grant...